{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Toxicity data will be reported as descriptive data as the percentage of patients experiencing reported side effects. Toxicity and safety analyses will be conducted using the safety analysis set.","groups":[{"description":"This is a single-arm, single-stage, open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms.\n\nAll subjects will receive topical fluocinonide 0.05% cream to apply twice daily for two weeks and then once daily for two weeks to the vagina. The duration of treatment will be 4 weeks.","id":"OG000","title":"Supportive Care (Fluocinonide Cream)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Toxicity and safety analyses will be conducted using the safety analysis set.","reportingStatus":"POSTED","timeFrame":"Over 4 weeks","title":"Number of Patients Experiencing Toxicities","type":"SECONDARY","unitOfMeasure":"Participants"}